FDA approves new cholinesterase inhibitor for Alzheimer's disease.
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D048448:Phenylcarbamates; D000068836:Rivastigmine; D014481:United States; D014486:United States Food and Drug Administration
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine